G22恒峰(中国)

專注给予質高價優

的生物藥

科學論文

Preclinical characterization of a potential best-in-class camptothecin-based antibody-drug conjugate targeting ADAM metallopeptidase domain 9
AACR 2026
Hanjugator camptothecin platform: Effective, low-toxicity design maximizing antibody functionality and delivering potential best-in-class cMet/EGFR bispecific antibody-drug conjugate
AACR 2026
A Best-in-Class HER2xHER2 Novel Biparatopic Antibody-Drug Conjugate with an Efficacious, Low-Toxicity Design that Maximizes Antibody Functionality
AACR 2026
A novel anti-CD3xCD28xSTEAP1 trispecific T-cell engager (HLX3902) with enhanced and durable antitumor responses in prostate cancer
AACR 2026
Preclinical Studies Reveal that Protease-Mediated Payload Release and Immuno-Oncology/Immunomodulatory Effects Contribute to the Antitumor Activity of HLX43
AACR 2026
A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as firstline therapy in advanced or recurrent squamous non-small cell lung cancer
ASCO 2025

知識產權

專利申請數量	PCT申請數量	國內外授權專利數量	註冊司法權區	申請日期	到期日	發明專利數量
809	90	134	中國大陸	2011-03-18	2031-03-18	97